Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens

Trial Profile

Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Dendritic cell vaccines-Medigene Immnotherapies (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MediGene AG
  • Most Recent Events

    • 23 Mar 2017 According to a Medigene media release, final data expected for late 2019.
    • 23 Mar 2017 According to MediGene AG media release, treatment of the first patient in the Phase II part of the trial commenced in April 2016.
    • 23 Mar 2017 According to MediGene AG media release,company expects completion of patient recruitment in the course of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top